# Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function

> **NCT04116476** · PHASE1 · COMPLETED · sponsor: **Tanabe Pharma America, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Mild and Moderate Hepatic Impairment

## Interventions

- **DRUG:** MT-7117

## Key facts

- **NCT ID:** NCT04116476
- **Lead sponsor:** Tanabe Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-01
- **Primary completion:** 2021-02-16
- **Final completion:** 2021-02-16
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04116476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04116476, "Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04116476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*